NCT01044810

Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

Comparison of Virological and Immunological Results of Efavirenz-based Regimen in HIV-infected Patients With or Without Allergic Reactions to Nevirapine

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 559 (actual)
• Sponsor: Bamrasnaradura Infectious Diseases Institute · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP and continued the other NRTIs for a period of time, i.e. "staggered interruption"; and (3) started EFV-based regimens as an initial regimen (as controlled group).

Conditions

• Treatment Failure, HIV or AIDS
• CD4 Cell Counts

Interventions

Type	Name	Description
DRUG	Efavirenz-based regimens	Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2010-01-08
• Last updated: 2011-03-15

Locations

1 site across 1 country: Thailand